Polymorphism in MHC class II transactivator gene is not associated with susceptibility to colorectal cancer in Swedish patients.
Reduced expression of major histocompatibility complex class II (MHC-II) genes in colorectal cancer (CRC) has been reported. MHC-II transactivator (CIITA), encoded by the MHC2TA gene, is considered to be the master regulator for MHC-II gene expression. A functional single nucleotide polymorphism (SNP) -168A-->G in the promoter region of the MHC2TA gene is suggested to have an influence on different autoimmune diseases. Our study was performed to evaluate the association between the -168A-->G MHC2TA gene variant in patients with CRC versus a control group. Using the TaqMan system, this SNP was screened in 248 CRC patients and 256 controls. No significant difference in genotype distribution or in allelic frequencies was found between the two groups, nor any association with clinical characteristics. The results of this study suggest that -168A-->G polymorphism of the MHC2TA gene is not associated with susceptibility to CRC.